Treprostinil to Reverse Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis as a Bridge to Single-Lung Transplantation

Journal of Heart and Lung Transplantation

Volumn 28, Issue 9, 2009, Pages 964-967

  Saggar, Rajeev ^a   Shapiro, Shelley S ^a,b   Ross, David J ^a   Fishbein, Michael C ^a   Zisman, David A ^a   Lynch III, Joseph P ^a   Weigt, Sam S ^a   Ardehali, Abbas ^a   Belperio, John A ^a   Saggar, Rajan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SILDENAFIL; UNIPROST;

AGED; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE TITRATION; DYSPNEA; EXERCISE TEST; FEMALE; GERIATRIC PATIENT; HEART CATHETERIZATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SPIROMETRY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; LUNG TRANSPLANTATION; PIPERAZINES; PURINES; SPIROMETRY; SULFONES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 68949210381     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.05.017     Document Type: Article

References (20)

1. Trulock E.P., Christie J.D., Edwards L.B., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 26 (2007) 782-795
2. Behr J., and Ryu J.H. Pulmonary hypertension in interstitial lung disease. Eur Respir J 31 (2008) 1357-1367
3. Lettieri C.J., Nathan S.D., Barnett S.D., Ahmad S., and Shorr A.F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129 (2006) 746-752
4. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
5. Collard H.R., Anstrom K.J., Schwarz M.I., and Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131 (2007) 897-899
6. Demedts M., and Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J 19 (2002) 794-796
7. Dandel M., Lehmkuhl H.B., Mulahasanovic S., et al. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment. J Heart Lung Transplant 26 (2007) 898-906
8. Raghu G., Weycker D., Edelsberg J., Bradford W.Z., and Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174 (2006) 810-816
9. Nadrous H.F., Pellikka P.A., Krowka M.J., et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128 (2005) 2393-2399
10. Whelan T.P., Dunitz J.M., Kelly R.F., et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 24 (2005) 1269-1274
11. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
12. Minai O.A., Sahoo D., Chapman J.T., and Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir Med 102 (2008) 1015-1020
13. Fisher K.A., Serlin D.M., Wilson K.C., Walter R.E., Berman J.S., and Farber H.W. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 130 (2006) 1481-1488
14. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
15. Colombat M., Mal H., Groussard O., et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: Histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 38 (2007) 60-65
16. Cruz-Gervis R., Stecenko A.A., Dworski R., et al. Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis. Respir Res 3 (2002) 17
17. Lovgren A.K., Jania L.A., Hartney J.M., et al. COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 291 (2006) L144-L156
18. Kallen A.J., Lederman E., Balaji A., et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 29 (2008) 342-349
19. Leuchte H.H., Baumgartner R.A., Nounou M.E., et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 173 (2006) 744-750
20. Simonneau G., Rubin L.J., Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149 (2008) 521-530